Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_assertion description "[Sunitinib is currently being evaluated in advanced human thyroid carcinomas, based on the rationale that the vascular endothelial growth factor and platelet-derived growth factor receptors and the RET/PTC rearrangement are valuable targets for the treatment of this malignancy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_assertion evidence source_evidence_literature NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_assertion SIO_000772 22442268 NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_assertion wasDerivedFrom befree-20150227 NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_assertion wasGeneratedBy ECO_0000203 NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.
- befree-20150227 importedOn "2015-02-27" NP671256.RAHphiWQ2EcNMwJbroW0GqFnA7l5m1q5mpULlkz6TVXeE130_provenance.